Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or ... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-0863440... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the e... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells'. The f... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Sa... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants wi... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Effica... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bev... Read More